Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
20813198

DOI
10.1016/j.bbmt.2010.08.018

Indexing Status
Subject indexing assigned by NLM

MeSH
Adult; Aged; Antigens, CD34 /analysis; Antineoplastic Agents /administration & dosage; Blood Component Removal /economics /utilization; Case-Control Studies; Cost-Benefit Analysis; Cyclophosphamide /administration & dosage; Female; Granulocyte Colony-Stimulating Factor /administration & dosage; Health Care Costs; Hematopoietic Stem Cell Mobilization /economics /methods; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds /administration & dosage; Humans; Male; Middle Aged; Retrospective Studies; Transplantation, Autologous; United States

AccessionNumber
22011000769

Date bibliographic record published
24/08/2011